Calcineurin signaling and NFAT activation in cardiovascular and skeletal muscle development  by Schulz, Robert A & Yutzey, Katherine E
www.elsevier.com/locate/ydbio
Developmental Biology 266 (2004) 1–16Review
Calcineurin signaling and NFAT activation in cardiovascular
and skeletal muscle development
Robert A. Schulza,* and Katherine E. Yutzeyb
aDepartment of Biochemistry and Molecular Biology, Graduate Program in Genes and Development, The University of Texas M.D. Anderson Cancer Center,
Houston, TX 77030, USA
bDivision of Molecular Cardiovascular Biology, Children’s Hospital Medical Center, Cincinnati, OH 45229, USAReceived for publication 2 September 2003, revised 7 October 2003, accepted 7 October 2003Abstract
Calcineurin signaling has been implicated in a broad spectrum of developmental processes in a variety of organ systems. Calcineurin is a
calmodulin-dependent, calcium-activated protein phosphatase composed of catalytic and regulatory subunits. The serine/threonine-specific
phosphatase functions within a signal transduction pathway that regulates gene expression and biological responses in many developmentally
important cell types. Calcineurin signaling was first defined in T lymphocytes as a regulator of nuclear factor of activated T cells (NFAT)
transcription factor nuclear translocation and activation. Recent studies have demonstrated the vital nature of calcium/calcineurin/NFAT
signaling in cardiovascular and skeletal muscle development in vertebrates. Inhibition, mutation, or forced expression of calcineurin pathway
genes result in defects or alterations in cardiomyocyte maturation, heart valve formation, vascular development, skeletal muscle
differentiation and fiber-type switching, and cardiac and skeletal muscle hypertrophy. Conserved calcineurin genes are found in invertebrates
such as Drosophila and Caenorhabditis elegans, and genetic studies have demonstrated specific myogenic functions for the phosphatase in
their development. The ability to investigate calcineurin signaling pathways in vertebrates and model genetic organisms provides a great
potential to more fully comprehend the functions of calcineurin and its interacting genes in heart, blood vessel, and muscle development.
D 2003 Elsevier Inc. All rights reserved.Keywords: Calcineurin; NFAT; Signal transduction; Cardiomyocyte; Hypertrophy; Valvuloseptal development; Vascular development; Skeletal muscle; Fiber-
type specialization; Drosophila; Interacting genes; Indirect flight muscle; C. elegansIntroduction
Calcineurin signaling transduced by nuclear factor of
activated T cells (NFAT) activation was first characterized
in the immune system (Flanagan et al., 1991; Matilla et al.,
1990). Calcineurin (also called protein phosphatase 2B or
PP2B) was originally identified as a calcium-regulated en-
zyme complex composed of calcineurin A (CnA) catalytic
and calcineurin B (CnB) regulatory subunits (Fig. 1), and the
calcium-binding protein calmodulin (reviewed in Rusnak and
Mertz, 2000). Substrates of calcineurin phosphatase activity
include most members of the NFAT family of transcription
factors. Four NFATc genes, nfatc1–c4, have been identified
with distinct temporally and spatially regulated expression
patterns (reviewed in Pan et al., 1997; Rao et al., 1997). A
related rel-like protein, NFAT5, has also been reported with0012-1606/$ - see front matter D 2003 Elsevier Inc. All rights reserved.
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E-mail address: raschulz@mdanderson.org (R.A. Schulz).DNA binding specificity and regulatory interactions distinct
from NFATc1–c4 (Macian et al., 2001). Loss of specific
NFAT isoforms results in cardiovascular, skeletal muscle,
cartilage, neuronal, or immune system defects (Bushdid et al.,
2003; de la Pompa et al., 1998; Graef et al., 2001a, 2003;
Kegley et al., 2001; Peng et al., 2001; Ranger et al., 1998,
2000). Calcineurin and NFATs have also been implicated in
the differentiation of bone, cartilage, muscle, skin, and fat in
tissue culture experiments (Abbott et al., 1998; Delling et al.,
2000; Friday et al., 2000; Ho et al., 1998; Santini et al., 2001;
Takayanagi et al., 2002; Tomita et al., 2002). Postnatally, this
signaling pathway contributes to normal homeostasis as well
as pathological conditions in the skin, cardiovascular system,
skeletal muscle, immune cells, and central nervous system
(Al-Daraji et al., 2002; Baksh and Burakoff, 2000; Molken-
tin, 2000;Molkentin et al., 1998). These are many of the same
organ systems that require calcineurin/NFATsignaling during
embryonic development. Thus, there is accumulating evi-
dence for the widespread utilization of calcineurin/NFAT
Fig. 1. Calcineurin subunits and NFATc isoforms in mouse, Drosophila, and C. elegans. Conserved protein domains of calcineurin A, calcineurin B, and
NFATc are presented, with known mouse, fly, and worm genes listed to the right. The regulatory part of calcineurin A includes calcineurin B and calmodulin
interacting regions and an autoinhibitory domain. The four conserved EF-hand calcium-binding domains (C) of calcineurin B are indicated. Within NFATc, the
transactivation domain (TAD) is located at the N-terminus, adjacent to a regulatory domain containing sequences required for calcineurin binding, serine-rich
motifs, and nuclear localization signals. The conserved DNA binding domain is of the rel homology class.
R.A. Schulz, K.E. Yutzey / Developmental Biology 266 (2004) 1–162signaling mechanisms in a broad spectrum of developmental
and disease processes.
Calcineurin dephosphorylates NFATs in response to
increased intracellular calcium and regulates gene expres-
sion in a variety of calcium-sensitive tissues such as brain,
muscle, and lymphocytes (reviewed in Baksh and Burakoff,
2000; Crabtree, 1999; Rusnak and Mertz, 2000). Transcrip-
tional activity of NFATs is dependent on dephosphorylation
by calcineurin, which leads to nuclear translocation (Beals
et al., 1997a). NFATs can be deactivated and localized in the
cytoplasm through phosphorylation by several protein
kinases including glycogen synthase kinase-3 (GSK-3),
protein kinase A, p38, JNK, and casein kinase (Beals et
al., 1997b; Chow et al., 1997; Sheridan et al., 2002; Yang et
al., 2002; Zhu et al., 1998). An additional level of regulation
of calcineurin activity is through calcineurin interacting
proteins including Cabin/Cain and Modulatory Calci-
neurin-Interacting Protein 1 (MCIP1)/Down syndrome Crit-
ical Region 1 (DSCR1) (Rothermel et al., 2003). NFAT
transcription factors contain a conserved calcineurin binding
domain and a rel homology DNA binding domain (Rao et
al., 1997). An NFATc1–c4 consensus binding sequence of
(A/T)GGAAA has been defined based on target sequences
in cytokine gene regulatory regions (Rao et al., 1997).
NFATs bind DNA with low affinity and usually act in
conjunction with other transcription factors such as AP-1,
MEF2, or GATA4 (Macian et al., 2001; Molkentin et al.,
1998; Naya et al., 2000; Rao et al., 1997). During early
development, NFATs are involved in establishing antero-
posterior polarity in Xenopus in conjunction with nonca-
nonical Wnt signaling (Saneyoshi et al., 2002). Thus, the
control of NFAT transcriptional regulatory activity in asso-
ciation with other proteins likely represents a nodal point in
intersecting signal transduction pathways including calci-
neurin, MAPK, p38, JNK, and Wnt (Crabtree, 1999; Crab-tree and Olson, 2002; Gitler et al., 2003; Saneyoshi et al.,
2002).
Highly conserved calcineurin subunit genes are also
found in invertebrate model organisms such as Drosophila
melanogaster and Caenorhabditis elegans (Fig. 1), and
recent genetic studies have demonstrated pleiotropic func-
tions for calcineurin in fly and worm development (Ban-
dyopadhyay et al., 2002; Gajewski et al., 2003; Kuhara et
al., 2002; Sullivan and Rubin, 2002). These include require-
ments in neural and muscular tissues that are among the
organ systems affected in vertebrate embryos with altered
calcineurin and NFAT signaling. Given the wide-ranging
roles for the phosphatase in diverse animal species and their
life processes, we focus this review on the functions of
calcineurin signaling and NFAT activation in heart, blood
vessel, and muscle formation. As abnormal development or
physiological function of these tissues is of clear health
relevance, we also address certain disease-related aspects of
altering calcineurin/NFAT signal transduction.Calcineurin/NFAT regulation of cardiomyocyte
maturation and hypertrophy
Calcineurin signaling and NFAT activation are required for
heart development
During embryonic and fetal development, cardiomyocytes
become progressively more specialized at molecular, meta-
bolic, morphological, and physiological levels (Rosenthal
and Xavier-Neto, 2000; Yutzey and Kirby, 2002). The mat-
uration of cardiomyocytes is fundamental to cardiac function
and embryonic viability and includes the atrial or ventricular
restricted expression of contractile protein, metabolic, and
calcium handling genes (Conway et al., 2003; Gregorio and
R.A. Schulz, K.E. Yutzey / Developmental Biology 266 (2004) 1–16 3Antin, 2000; Lyons, 1994). Among the genes regulated in
fetal cardiomyocytes inmice are a- and b-myosin heavy chain
(MyHC), atrial natiuretic factor (ANF), brain natiuretic
protein (BNP), myosin light chain 2a (MLC2a), phospho-
lamban, and SERCA-2 (Franco et al., 1998; Lyons, 1994).
Oxidative metabolic genes are likewise up-regulated during
the embryonic to fetal transition at midgestation with a shift
from glycolytic towards oxidative metabolism and increased
mitochondrial function that accompanies increased cardiac
demand (Fantel and Person, 2002; Ruiz-Lozano et al., 1998;
Shepard et al., 1998). Many of these same contractile protein
and metabolic genes are regulated in the adult cardiac
hypertrophic response (Fig. 2). The involvement of calci-
neurin signaling and NFAT activation in the adult cardiac
hypertrophic response (see below) led to the investigation of
the role of this signal transduction pathway in developmental
regulation of cardiac gene expression and function.
Calcineurin signaling and NFAT activation do not appear
to be required for the initial events of heart formation. Mouse
embryos with targeted mutations of calcineurin subunits or
NFAT genes undergo normal heart tube formation and
cardiomyocyte differentiation (Graef et al., 2001a; Kayyali
et al., 1999; Zhang et al., 1996). Differentiated heart tubes
were observed in embryos with mutations in the cnb1 gene,
which has been described as the only CnB isoform expressed
in the embryo, making it essential for any calcineurin signal
transduction (Graef et al., 2001a). Embryos lacking three of
the four NFATc family members, NFATc2–c4, also haveFig. 2. Calcineurin signaling and NFAT activation in cardiac muscle. In the
adult heart, hypertrophic stimuli lead to increased levels of intracellular
calcium triggering a cascade of calcineurin activation, NFAT nuclear
translocation, and increased gene expression. Target genes of NFATs,
functioning with GATA factors, include adss1 and BNP. A similar cascade
of calcineurin/NFAT signaling may be acting in the developing heart where
NFATc3 and NFATc4 together are required for metabolic activity and
myocardial maturation at midgestation.apparently normal heart tube formation (Graef et al., 2003).
In addition, pharmacological inhibition of calcineurin signal-
ing with cyclosporine A (CsA) treatment of early stage mouse
or chicken embryos failed to inhibit initial heart tube forma-
tion or cardiomyocyte differentiation (Graef et al., 2001a;
Liberatore and Yutzey, 2004). Primary diversification of
atrial and ventricular cardiomyogenic lineages also was
unaffected by calcineurin inhibition in avian embryos. To-
gether, these studies support the hypothesis that calcineurin
signaling is not required for the earliest events of heart
formation in the vertebrate systems examined.
Targeted mutations of NFAT genes in mice have revealed
multiple roles for these transcription factors later in cardio-
myocyte maturation and heart chamber formation. At least
two NFAT proteins, NFATc3 and NFATc4, are present in the
developing myocardium and NFATc1 is expressed in devel-
oping heart valves (de la Pompa et al., 1998; Graef et al.,
2001a; Ranger et al., 1998). The loss of both NFATc3 and
NFATc4 results in embryonic lethality at approximately
E10.5, although mice lacking either of the factors are viable
(Bushdid et al., 2003; Graef et al., 2001a; Oukka et al., 1998;
Wilkins et al., 2002). nfatc3/nfatc4/ embryos presented
with cardiovascular abnormalities and heart failure at E10.5,
but primary cardiomyocyte differentiation and chamber
specification were not affected (Bushdid et al., 2003; Graef
et al., 2001a). Nonetheless, the midgestational metabolic
transition and mitochondrial function were compromised in
the mutant embryonic hearts (Bushdid et al., 2003). Restoring
NFAT activity specifically in the heart by transgene expres-
sion using the a-MyHC promoter prolonged embryonic
viability, indicating defective cardiomyocyte maturation
was the primary cause of death in the nfatc3/nfatc4/
embryos. Therefore, normal fetal cardiac mitochondrial
maintenance and energy metabolism are dependent on NFAT
activity, although the precise molecular mechanisms for this
dependence are still unknown.
Additional genetic evidence exists for the importance of
calcineurin signaling and NFAT activation in cardiomyo-
cytes in mice. In the maturing atria, expression of a
dominant-negative NFAT late in fetal development leads
to thinning of the myocardium and loss of contractile
protein expression (Schubert et al., 2003). Similar hypo-
morphic development of the ventricular myocardium was
observed with the loss of calreticulin, a calcium-binding
protein important for intracellular calcium homeostasis
(Mesaeli et al., 1999). The embryonic lethality of calreti-
culin-deficient mice can be rescued with cardiac-specific
expression of activated calcineurin, suggesting calcineurin
signal transduction regulated by calreticulin is required for
maturation of the developing myocardium (Guo et al.,
2002). Proteins that interact with calcineurin, including
calsarcins and MCIP1/DSCR1, are also developmentally
regulated in the mouse embryonic myocardium with early
chamber specificity (Casas et al., 2001; Frey et al., 2000;
Lange et al., 2004). Together, these studies provide addi-
tional evidence for the importance of calcineurin signaling
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of the developing heart.
Calcineurin signaling and NFAT activation regulate the
adult cardiac hypertrophic response
The importance of calcineurin signaling and NFAT
activation in cardiac muscle was first discovered in the
hypertrophic response of adult cardiomyocytes (Molkentin
et al., 1998). Cardiac hypertrophy is defined as an adaptive
change in heart size due to an increase in cardiomyocyte cell
volume (reviewed in Molkentin, 2000). Hypertrophic
growth occurs in response to several intrinsic and extrinsic
stimuli, and while initially beneficial to maintain cardiac
contractile performance, sustained hypertrophy can lead to
cardiomyopathy and heart failure. Calcium-dependent sig-
naling pathways have been documented in several models of
cardiac hypertrophy and calcineurin has been implicated as
a central player based on the following experimental evi-
dence. First, the calcineurin inhibitors CsA and FK506
prevent hypertrophy of cardiomyocytes cultured in the
presence of hypertrophic agonists such as angiotensin II
and phenylephrine (Molkentin et al., 1998). Second, trans-
genic mice expressing a constitutively activated form of
calcineurin A in the heart show a dramatic cardiac enlarge-
ment that progresses to heart failure and sudden death. This
calcineurin-induced myopathy, and heart disease associated
with three other mouse models of cardiac hypertrophy, are
prevented by administration of CsA and FK506 (Molkentin
et al., 1998; Sussman et al., 1998). Third, forcing the cardiac
expression of an activated form of NFATc3 in mice culmi-
nates in a hypertrophic heart. Subsequent studies by several
investigators have supported the initial observation that
activation of the calcineurin/NFAT signal transduction path-
way is both necessary and sufficient for this hypertrophic
response (reviewed in Crabtree and Olson, 2002; Molkentin,
2000).
A model has been proposed wherein calcineurin trans-
duces the calcium signal generated by sarcomeric dysfunc-
tion, mechanical load, or chemical agonists through
dephosphorylation and activation of an NFAT transcription
factor (Olson and Williams, 2000b; Fig. 2). The nuclear
NFAT protein would then cooperate with cardiac expressed
transcription factors to initiate the hypertrophic gene ex-
pression program. The changes in gene expression that
occur with adult cardiac hypertrophy are often considered
to be a reactivation of the fetal ventricular gene expression
profile (Chien et al., 1993; Sadoshima and Izumo, 1997).
These changes include increased b-MyHC, ANF, and BNP
expression and decreased SERCA-2 and a-MyHC expres-
sion. BNP and the cardiac metabolic gene adenylosuccinate
synthetase 1 (adss1) are direct transcriptional targets of
NFAT, acting in conjunction with GATA4 (Fig. 2; Molken-
tin et al., 1998; Xia et al., 2000). Thus, the calcineurin/
NFAT pathway directly regulates at least some aspects of
cardiac muscle remodeling in the adult hypertrophic re-sponse in addition to being required for the maturation of
cardiomyocytes during development.NFAT and heart valvuloseptal development
The first evidence of primitive valve formation in the
developing vertebrate embryo is the induction of endocardial
cushions at the atrioventricular (AV) junction and the outflow
tract (OFT). Endocardial cushion formation is initiated in
response to signals emanating from the outer myocardial
layer that induce the endocardium to undergo an epithelial to
mesenchymal transition and invade the intervening cardiac
jelly (Eisenberg and Markwald, 1995). The cushions are later
remodeled into fibrous valves and membranous/muscular
septa that divide the heart into four chambers. While endo-
cardial cushion formation has been studied for many years
and growth factors involved in this process identified, rela-
tively little is known about the maturation of the cushions into
functional valves (Camenisch et al., 2002; Eisenberg and
Markwald, 1995). The remodeling of the mesenchymal
endocardial cushion tissue into valves includes the reorgani-
zation of the extracellular matrix into highly organized valve
leaflets (Icardo and Colvee, 1995; Icardo et al., 1993).
Regulatory mechanisms that control the transformation of
the cushions into valve leaflets and supporting structures are
not well defined. However, the NFATc1 protein is emerging
as an essential regulator of this process (Fig. 3).
The requirement for NFAT activity in valvuloseptal de-
velopment was first demonstrated in nfatc1 null embryos (de
la Pompa et al., 1998; Ranger et al., 1998). Such embryos die
due to valvuloseptal defects including hypomorphic semilu-
nar and AV valves, as well as ventricular septal defects.
During valve formation, nfatc1 gene expression is restricted
to the endothelial cell layer of the endocardial cushions and
nuclear localization of NFATc1 in the AV canal endothelium
is observed as early as E10.5. However, endocardial cushion
formation and the initial septation of the OFT into aortic and
pulmonary channels are apparently normal in nfatc1 null
embryos. Therefore, the developmental lesion(s) caused by
nfatc1 deficiency is likely in the later maturation of the
endocardial cushions into valvuloseptal structures. However,
the precise molecular nature of these congenital heart abnor-
malities that result from loss of NFATc1 is not known. In
avian embryos, cnaa and cnab are preferentially expressed in
the AV canal and OFT endocardial cushion formations, as
well as in the maturing AV and semilunar valves (Liberatore
and Yutzey, 2004). Together, these studies support the neces-
sity of calcineurin signaling and NFATc1 activation in val-
vuloseptal development by a yet undefined mechanism.
In adult human pulmonary valve endothelial cells, nuclear
localization of activated NFATc1 and cell proliferation are
induced with increased vascular endothelial growth factor
(VEGF) signaling (Johnson et al., 2003). VEGF activation of
NFATc1 is inhibited by CsA treatment, suggesting that VEGF
functions through calcineurin activation. The requirement for
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observed in vascular endothelial cells (see below). There is
preliminary evidence that adult valve disease recapitulates at
least some aspects of embryonic valve development (Johnson
et al., 2003; Paranya et al., 2001). Therefore, VEGF signaling
mediated by NFATc1 may also regulate endothelial cell
proliferation during embryonic valvuloseptal development.
Support for this regulatory interaction is provided by studies
in genetically altered mice demonstrating that gain or loss of
VEGF activity leads to embryonic death as a result of
cardiovascular malformations including valvuloseptal
defects (Carmeliet et al., 1996; Dor et al., 2001; Ferrara et
al., 1996; Miquerol et al., 2000). However, the relationship
between VEGF signaling and NFAT activation during valvu-
loseptal development remains to be determined.
The signal transduction pathways that regulate NFATc1
activation in the developing heart valves also likely intersect
with neurofibromin (NF1) and MAPK signaling (Gitler et
al., 2003). NF1 encodes a tumor suppressor gene associated
with neurofibromatosis type 1, a genetic disorder character-
ized by tumors and cardiovascular defects (Bollag et al.,
1996; Friedman et al., 2002). Endothelial-specific loss of
NF1, a Ras inhibitor, results in increased MAPK phosphor-
ylation and enlarged endocardial cushions (Gitler et al.,
2003; Lakkis and Epstein, 1998). Premature nuclear local-
ization of NFATc1 also was observed in endocardial cells of
NF1/ embryos and in endothelial cells expressing consti-
tutively active Ras (Gitler et al., 2003). In contrast, de-
creased nuclear localization of NFATc1 in endocardial
endothelial cells was observed in mouse embryos lacking
connexin45 (Cx45), which die of heart failure at approxi-
mately E10 (Kumai et al., 2000). The mechanism by which
loss of Cx45 leads to reduced NFATc1 nuclear localization
has not been identified, but VEGF has been demonstrated to
activate connexin gene expression in neonatal cardiomyo-
cytes (Pimentel et al., 2002). Together, these studies suggest
that NFATc1 nuclear localization and transcriptional activity
in endocardial endothelial cells are regulated by intersecting
signal transduction pathways (Fig. 3).
The transcriptional targets for NFATc1 in the AV canal
and OFT have not been thoroughly described. Recently,
endothelin-1 has been identified as a direct downstream
target of NFATc1 and GATA5 in cultured TC13 endothelial
cells (Nemer and Nemer, 2002). An additional target of
NFATc1 in AV and OFT endothelial cells appears to be the
dscr1/mcip1 gene (Lange et al., 2004; Rothermel et al.,
2000; Yang et al., 2000). DSCR1 is expressed in the AVand
OFT valve endothelial cells and is enriched in the forming
septa of the mouse heart, which is consistent with the often
severe valvuloseptal abnormalities associated with Down
syndrome/trisomy 21 (Freeman et al., 1998; Lange et al.,
2004). The alternative exon 4 promoter of dscr1/mcip1 is
responsive to calcineurin activity via a dense cluster of
conserved NFAT consensus binding sequences (Yang et al.,
2000). This dscr1/mcip1 NFAT-rich regulatory region is
specifically expressed in the AV valve endothelial cells intransgenic mice and the expression of the dscr1/mcip1
NFAT-rich regulatory region is dependent on NFATc1
(Lange et al., 2004). The function of dscr1/mcip1 in valve
development is not known, but the NFATc1-dependent
expression of the dscr1/mcip1 calcineurin response element
in valve primordial endothelial cells is further support for
the importance of calcineurin/NFAT signal transduction
during valvuloseptal development.Calcineurin/NFAT regulation of vascular development
Blood vessel formation occurs throughout embryonic
development to meet the circulatory needs of the different
organ systems. This process has been described as occurring
by vasculogenesis followed by angiogenesis. Vasculogenesis
is the initial formation of a vascular plexus of differentiated
endothelial cells and angiogenesis or angiogenic remodeling
is the fusion and patterning of the endothelial cells in the
plexus to form larger vessels (Sato and Loughna, 2002;
Yancopoulos et al., 2000). Genetic studies in zebrafish and
mice have identified several growth factors and signaling
molecules involved in primary vasculogenesis and angioge-
nic remodeling during embryonic blood vessel development
(Rossant and Howard, 2002; Weinstein, 1999). Among these
are VEGF, which is involved in vasculogenesis and angio-
genesis, as well as fibroblast growth factor (FGF), angiopoie-
tin, platelet-derived growth factor (PDGF), transforming
growth factor-h (TGF-h), and ephrin family members (Poole
et al., 2001; Rossant and Howard, 2002). While many of the
ligands and receptors required for vascular development have
been identified, less is known about how the intracellular
signal transduction pathways intersect with transcriptional
regulatory factors. Initial studies in mouse and chicken
embryos, as well as in cultured endothelial cells, provide
evidence for a role for calcineurin signaling and NFAT
activation in the regulation of embryonic vascular develop-
ment (Fig. 3).
The roles for calcineurin signaling in early embryonic
vascular development were examined in mice with targeted
mutations of calcineurin or NFATc genes. In either cnb1 or
nfatc3/nfatc4mutant embryos, endothelial differentiation and
primary vascular plexus formation appeared normal. The
cnb1 mutant embryos do not develop beyond E9.5 and
exhibit defects in angiogenesis, apparent in the lack of fusion
and remodeling of the vascular plexus into larger vessels
(Graef et al., 2001a). Neither cnaa nor cnab mutant mice has
been reported to have vascular patterning defects and null
animals survive into adulthood (Bueno et al., 2002; Zhang et
al., 1996). Increased vascular plexus formation was also
observed in nfatc3/nfatc4 null embryos that survive to
E10.5. However, restoration of NFAT activity specifically
in the heart prolongs the viability of the nfatc3/nfatc4 null
embryos and restores apparently normal vascular develop-
ment at E10.5 (Bushdid et al., 2003). The restoration of
vascular development by cardiac-specific expression of
Fig. 3. Calcineurin signaling and NFAT activation in embryonic endocardial and vascular endothelial cells. Calcineurin/NFAT signaling pathways are shown for
primitive valve endothelial cells on the left and vascular endothelial cells on the right. In both systems, extracellular signaling can induce calcineurin activation
and NFATc nuclear translocation. VEGF, possibly induced by hypoxia, has been implicated as an activator of calcineurin signaling in both valve and vascular
endothelial cells. In the developing heart valves, NFATc1 nuclear translocation is enhanced by NF1 inhibition of Ras activity. Transcriptional targets of NFATs
in these tissues include the calcineurin interacting protein gene dscr1/mcip1 and the endothelin-1 gene. In vascular endothelial cells, activated NFATc2 is a
transcriptional regulator of cox-2 and tissue factor gene expression.
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are secondary to cardiac defects. Still other NFATs expressed
in the developing vasculature, such as NFATc2, could medi-
ate calcineurin signal transduction in the regulation of angio-
genic remodeling in the developing vasculature from E9 to
E11 (Bushdid et al., 2003; Graef et al., 2001a). Further studies
are necessary to dissect the precise calcineurin/NFAT signal-
ing events required for angiogenic remodeling and blood
vessel formation.
Studies of mouse and chicken embryos treated with CsA
provide additional evidence for the importance of calcineurin
signaling in early blood vessel development. Targeted muta-
genesis of the cnb1 gene affects the entire embryo, making it
difficult to pinpoint the precise temporal and spatial require-
ments for calcineurin signaling in the cardiovascular system.
Transient inhibition of calcineurin activity with embryonic
administration of CsA was used to examine the temporal
requirements for this signaling pathway. In mice, CsA treat-
ment from E7.5 to E8.5 leads to defects in vascular remodel-
ing similar to those observed in the cnb1 mutant embryos
(Graef et al., 2001a). These defects were not observed with
earlier or later CsA treatments. In avian embryos, CsA
administration during comparable stages also leads to vascu-
lar patterning defects. Together, these studies support the
early requirements of calcineurin signaling to potentiate
blood vessel development. The spatial requirements and
primary vs. secondary effects of calcineurin inhibition on
angiogenic remodeling were examined in avian embryos with
local applications of CsA. CsA infiltrated agar plugs were
placed directly on the developing vascular bed or near thedeveloping heart. Direct application of CsA to the remodeling
vessels did not prevent angiogenic remodeling, whereas
administration of CsA near the developing heart inhibited
blood vessel formation (Liberatore and Yutzey, 2004). These
studies support secondary effects of compromised heart
function as a result of altered calcineurin signaling on blood
vessel formation observed in the nfatc3/nfatc4 mutant mice.
Together, these studies underscore the complexity of the
temporal and spatial requirements for calcineurin/NFAT
signaling in the developing heart and vasculature.
Comparison of embryos with alterations in either calci-
neurin/NFAT function or VEGF signaling suggests these
pathways may intersect during vascular development. Stud-
ies in mice and chicken embryos indicate that VEGF signal-
ing is necessary and sufficient for the remodeling of the
primary capillary plexus into larger blood vessels during the
initial stages of vascular development (Argraves et al., 2002;
Carmeliet et al., 1996; Drake and Little, 1995; Ferrara et al.,
1996; Flamme et al., 1995). This sensitivity period is consis-
tent with the temporal and spatial requirements for calci-
neurin/NFAT signaling in early blood vessel remodeling
(Graef et al., 2001a; Liberatore and Yutzey, 2004). Intersec-
tion of these signaling pathways has already been demon-
strated in human umbilical vein endothelial cells (HUVEC)
and adult pulmonary valve endothelial cells where VEGF
induces calcineurin signaling and NFAT activation (Arme-
silla et al., 1999; Hernandez et al., 2001; Johnson et al., 2003).
In HUVECs, VEGF-induced angiogenesis and cyclooxyge-
nase-2 (cox-2) gene activation is inhibited by CsA treatment
(Hernandez et al., 2001). VEGF induces NFAT binding
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trans-activation by NFATs and induction by VEGF (Fig. 3).
VEGF signaling also induces tissue factor gene expression in
HUVECs, which is mediated by NFAT trans-activation of
binding sites in the tissue factor promoter (Armesilla et al.,
1999). These studies identified NFATc2 as the primary
mediator of VEGF signal transduction in the HUVEC system
(Armesilla et al., 1999; Hernandez et al., 2001). Further
studies are necessary to determine if VEGF function in
primary embryonic vasculature formation requires calci-
neurin/NFAT signaling and to identify the specific NFAT
family members involved.Calcineurin/NFAT control of skeletal muscle
development and differentiation
Requirement of NFAT proteins for skeletal muscle
development
The complex interplay of signaling systems and myogenic
regulatory genes in the formation of vertebrate skeletal
muscle has been the subject of comprehensive reviews
(Bailey et al., 2001; Buckingham, 2001) and thus will not
be addressed herein. The process of skeletal muscle forma-
tion occurs developmentally in two phases as sets of primary
myofibers are initially generated, followed by a second wave
of myofiber formation. Both myofiber groups undergo
growth through myotube fusion with additional myoblasts
and patterning within the developing muscle. NFAT proteins
show different functions in various aspects of this develop-
mental process.
Cultured human skeletal muscle cells express NFATc1,
NFATc2, and NFATc3 in three distinct stages of differenti-Fig. 4. Calcineurin and NFAT functions in skeletal myotube formation, myocyte
growth is the nuclear translocation of NFATc2 in the nascent myotube and IL-4 gr
form the mature myotube. Further molecular or electrical inputs can result in dram
and tonic motor nerve activity increase calcineurin-mediated signaling. The form
muscle hypertrophy, while the latter culminates in elevated NFAT and MEF2 activi
2003.ation: myoblasts, nascent myotubes, and mature myotubes
(Abbott et al., 1998). The proteins reside predominantly in
the cytoplasm under standard conditions, but when cultured
in the presence of the calcium ionophore ionomycin, indi-
vidual isoforms undergo an induced nuclear translocation at
specific stages of muscle differentiation. That is, NFATc3
moves into myoblast nuclei, NFATc2 translocates into
nascent myotube nuclei, and NFATc1 shuttles into nascent
and mature myotube nuclei. Forcing calcineurin expression
in C2C12 myoblasts by adenovirus-mediated gene transfer
also induces nuclear translocation of NFATc3, but not
NFATc1 and NFATc2 (Delling et al., 2000). Together, these
preferential translocation events are suggestive of NFAT
isoform specificity in the regulation of skeletal muscle gene
expression and development.
In support of this notion, an analysis of nfatc2 and nfatc3
knockout mice demonstrated distinct skeletal muscle defects
in the two mutants as compared to each other and wild-type
controls. In nfatc3/ animals, reduced muscle masses were
observed due to a decrease in the number of myofibers of
both the slow and fast types (Kegley et al., 2001). Defects in
muscle formation were traced back to early stages of myo-
genesis ongoing within the embryo, specifically a decrease
in the total number of primary myofibers. Since the size and
organization of formed myofibers appeared normal, and
such myofibers supported a conventional secondary myo-
genesis, it was concluded that NFATc3 served a specialized
role in primary myogenesis. Such a distinct function for this
isoform would occur if NFATc3 were active only in embry-
onic myoblasts that contribute to primary myofiber forma-
tion, but not in fetal myoblasts that are essential for
secondary myofiber production (Kegley et al., 2001).
nfatc2 knockout mice present a different type of muscle
abnormality, that being reduced muscle size due to a defecthypertrophy, and myofiber-type switching. A key event in skeletal muscle
owth factor secretion, which promotes a second phase of myoblast fusion to
atic alterations of skeletal muscle phenotype. Both the IGF-1 growth factor
er leads to enhanced NFATc1 and GATA2 activities resulting in skeletal
ties leading to myofiber-type switching. Adapted in part from Horsley et al.,
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analyses revealed a normal formation of nascent myofibers,
but these myofibers contained a limited number of nuclei
due to a lack of further growth-promoting myoblast fusion.
This phenotype, and the selective calcium-induced nuclear
translocation of NFATc2 in nascent myotubes of differenti-
ating muscle cells in culture (Abbott et al., 1998), are
consistent with a novel function for NFATc2 in the regula-
tion of myofiber and myoblast fusion, leading to the growth
of multinucleated muscle tubes. This could occur through
NFATc2 regulation of a cell surface protein within myofib-
ers, which mediates cell fusion with neighboring differen-
tiating cells, or NFATc2 regulation of a myofiber secreted
factor that attracts myoblasts to the growing syncytial
muscle (Horsley et al., 2001). Recent studies strongly
support the latter mechanism as the cytokine IL-4, expressed
under the control of NFATc2, is secreted by nascent myo-
tubes and attracts IL-4a receptor positive myoblasts, pro-
moting further cell fusion and mature myotube formation
(Horsley et al., 2003; Fig. 4). Taken together, the NFAT
localization studies and loss-of-function analyses point to a
differential contribution of NFAT isoforms to the control of
skeletal muscle development. As the NFATc2 and NFATc3
phenotypes appear unique when compared to those ob-
served in mice with disruptions of other myogenic factor
genes, NFAT protein activation likely represents a crucial
facet of this programmed developmental process.
Calcineurin activity is required for skeletal muscle
differentiation
A role for calcineurin in the terminal differentiation of
skeletal myocytes was initially suggested using cultured
cells and an in vivo muscle regeneration assay. Treating
human skeletal muscle cells with CsA prevented biochem-
ical and morphological differentiation of such cells, while
allowing normal proliferative properties (Abbott et al.,
1998). In mice, induction of a limb muscle injury is
normally followed by repair 12–14 days after damage.
However, in CsA-treated animals, such injured muscles fail
to heal and are largely devoid of regenerated myofibers. A
direct involvement of calcineurin in the differentiation
process was demonstrated in C2C12 and Sol8 myoblasts
(Delling et al., 2000). Activity of the phosphatase is in-
creased during myogenic differentiation of C2C12 cells and
forced expression of activated calcineurin in both C2C12
and Sol8 myoblasts enhances myotube formation. In con-
trast, expressing the calcineurin inhibitory protein Cain in
C2C12 cells culminated in decreased calcineurin activity
and the attenuation of myogenic differentiation. As noted
previously, activated calcineurin expression also results in a
specific nuclear translocation of NFATc3 within the cells.
Together, these findings implicate calcineurin signaling and
NFATc3 activation in the regulation of skeletal muscle cell
differentiation and myotube formation. Such in vitro results
are consistent with the muscle phenotype of nfatc3 knockoutmice, where mutant animals have muscles of reduced size
due to defects in primary myogenesis (Kegley et al., 2001).Calcineurin/NFAT control of skeletal muscle
hypertrophy and fiber-type specialization
Genetic control of skeletal muscle hypertrophy
While hypertrophic growth of cardiac muscle may ulti-
mately be harmful and potentially life threatening, analo-
gous growth of skeletal muscle in response to aging or
disease may be of clear benefit. The growth of skeletal
muscle due to prolonged use is a well-established physio-
logical response, yet the molecular pathways that regulate
such an adaptation have been poorly understood. Recent
studies have implicated calcineurin as an important regula-
tor of this cellular growth response. Specifically, a mouse
model has been established wherein the plantaris muscle of
the hind limb is subjected to functional overload in vivo,
resulting in a doubling of muscle mass and individual fiber
sizes, and increased muscle strength within a few weeks
(Dunn et al., 1999). However, when identical overloading
conditions were used with mice administered CsA or
FK506, such animals failed to undergo muscle compensa-
tion and enlargement. This result suggested a critical role for
calcineurin activity in the overload induced hypertrophy, but
the study did not address the function of an NFAT protein as
a downstream effector of calcineurin signaling.
Insulin-like growth factors (IGFs) are known to be potent
inducers of skeletal muscle growth and hypertrophy
(reviewed in Florini et al., 1991). A role for calcineurin in
IGF-1-induced skeletal muscle hypertrophy has been dem-
onstrated by two groups using myogenic cell cultures.
Transfecting IGF-1 into postmitotic rat L6E9 skeletal myo-
cytes results in an induction of cna gene transcripts and CnA
nuclear localization in hypertrophic myocytes (Musaro et
al., 1999). Similarly, introducing an activated form of
calcineurin into these cells phenocopies the effects of IGF-
1, while dominant-negative calcineurin expression or CsA
treatment prevents myocyte differentiation and hypertrophy.
Mechanistically, it was proposed that IGF-1 promotes hy-
pertrophy through the induction of calcineurin-mediated
signaling and the activation of the GATA2 transcription
factor. GATA2 associates with calcineurin and a dephos-
phorylated form of NFATc1 in some nuclei, culminating in
the activation of the myocyte hypertrophic gene expression
program (Fig. 4). Independent studies using C2C12 skeletal
muscle cells showed that transfection with IGF-1, or treat-
ment with a combination of insulin and dexamethasone,
resulted in hypertrophy of differentiated myotubes (Semsar-
ian et al., 1999). Calcineurin activation was demonstrated in
these cells, as well as inducement of NFATc1 nuclear
translocation. Consistent with the activation of the phospha-
tase, treatment of C2C12 cells with CsA blocked the
hypertrophic response to IGF-1 expression or duo hormone
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important insights into the control of skeletal muscle hyper-
trophy by the calcineurin/NFATc1 signaling pathway.
It should be noted, however, that the equivalence of the
calcineurin regulatory paradigm between skeletal and car-
diac muscle hypertrophy is likely more complex than
originally proposed. For example, expression of activated
calcineurin in skeletal muscles of mice does not cause
hypertrophy as seen in the heart (Naya et al., 2000).
Additional studies showed that CsA had either no effect
(Dupont-Versteegden et al., 2002) or differential effects
(Mitchell et al., 2002) on the maintenance of muscle mass
in animals exposed to atrophy-inducing stimuli. Other find-
ings suggested calcineurin did not mediate IGF-1-induced
skeletal muscle hypertrophy, rather the Akt/mTOR pathway
served as the critical regulator of this myotube growth
process (Bodine et al., 2001; Pallafacchina et al., 2002;
Rommel et al., 2001). Thus, while it is clear that calcineurin/
NFAT signaling plays some role in the hypertrophic re-
sponse of skeletal muscle, the precise function of this
pathway must be further investigated and deciphered.
Calcineurin and muscle fiber-type specialization
Skeletal muscle fibers can generally be classified as slow
or fast based on inherent metabolic and contractile proper-
ties, dependent on the degree of motor nerve stimulation and
the corresponding gene programs expressed within
(reviewed in Hughes, 1998; Olson and Williams,
2000a,b). Slow twitch fibers are subject to tonic motor
neuron activity, undergo sustained contractile events, and
maintain high concentrations of intracellular calcium. These
fibers are predominantly oxidative and express slow con-
tractile protein isoforms and metabolic enzymes that are
highly efficient in converting energy into contractile work.
In contrast, fast twitch fibers are exposed to sporadic motor
neuron input, exhibit bursts of contractile activity, and
maintain relatively low concentrations of intracellular calci-
um, with transient high-level spikes occurring during neu-
romuscular activity. Such fast fibers are glycolytic in nature
and express contractile protein isoforms and enzymes that
are essential for infrequent, robust bursts of contractile
work. Understanding the regulatory pathways that control
specialization and inter-conversion of these myofiber types
would be of potential benefit to both healthy individuals
engaged in exercise training and patients challenged by
various myopathies or physical inactivity.
Several lines of evidence have demonstrated the impor-
tance of calcineurin signaling in the control of skeletal muscle
fiber-type specialization. First, forcing the expression of an
activated form of calcineurin in C2C12 cell cultures resulted
in promoter activation of several slow myofiber-specific
genes, including MyHC, troponin I, and myoglobin (Chin et
al., 1998; Delling et al., 2000). Calcineurin-dependent regu-
lation of the latter two was implicated to be through the
combinatorial function of NFAT and MEF2 class transcrip-tion factors (Chin et al., 1998). In contrast, the promoter for
the fast myofiber muscle creatine kinase (MCK) gene failed
to be activated under comparable transfection conditions.
Second, studies in whole animals have confirmed the ability
of calcineurin to activate the slow fiber gene expression
program. Targeted mutagenesis of cnaa and cnab in mice
leads to a reduction in oxidative/slow fibers in several
muscles (Parsons et al., 2003). Conversely, transgenic mice
expressing activated calcineurin under the control of the
MCK enhancer exhibited increased numbers of slow-type
myofibers (Naya et al., 2000). Likewise, injection of a
recombinant adenovirus expressing activated calcineurin into
the gastrocnemius muscle of neonatal rats led to an enhanced
expression of the slow MyHC isoform in normally fast
expressing areas, coincident with the accumulation of acti-
vated calcineurin protein (Delling et al., 2000). Third, studies
involving CsA have yielded complementary data in support
of calcineurin’s role in muscle remodeling in vivo. Specifi-
cally, intraperitoneal administration of the calcineurin inhib-
itor promoted a pronounced slow to fast fiber transformation
within soleus muscles of treated rats (Chin et al., 1998). Also,
the fast to slow fiber conversions normally observed in
overloaded mice failed to occur when such animals were
administered CsA (Dunn et al., 1999).
Taken together, these findings are consistent with a
model that explains how motor nerve activity controls
specific muscle gene expression programs, culminating in
slow versus fast fiber types (Chin et al., 1998). In slow
fibers, tonic motor nerve activity results in sustained levels
of intracellular calcium sufficient to induce calcineurin
signaling and NFAT activation. Nuclear NFAT proteins
would then work combinatorially with MEF2 (and other)
transcription factors to regulate slow fiber-expressed genes
(Fig. 4). In fast fibers, phasic motor nerve activity is
insufficient to maintain calcium concentrations that are
required for calcineurin activation and NFAT nuclear trans-
location. Subsequently, genes encoding fast fiber-type pro-
tein isoforms would be transcribed as they are independent
of NFAT regulation. Based on these regulatory controls,
selective induction or inhibition of calcineurin phosphatase
activity would result in altered gene expression programs
and corresponding muscle fiber-type conversions.
In addition to NFAT proteins, there is emerging evidence
for MEF2 family members being direct targets of calci-
neurin activity in skeletal muscles. Using transgenic mice
harboring a putative MEF2-dependent reporter gene (Naya
et al., 1999), calcineurin was shown to be essential for the
functional activation of MEF2 in the reprogramming of
myofiber-specific gene expression during the physiological
adaptation of exercised muscles (Wu et al., 2001). The
phosphatase can physically interact with MEF2 so as to
remove phosphate groups, with the hypo-phosphorylated
factor showing enhanced transcriptional activation proper-
ties. The effect in actively contracting muscles is the up-
regulation of previously repressed MEF2 target genes,
leading to a transition from the resting IIb fiber type to
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calcineurin can mediate the dephosphorylation of NFATc1,
MEF2A, and MEF2D proteins to an extent that is dependent
on the degree of muscle nerve activity and resulting intra-
cellular calcium levels (Dunn et al., 2001). Such a finding is
consistent with the aforementioned model wherein slow
muscle fibers are conducive to calcineurin activation, since
they receive a tonic motor nerve input that sustains elevated
calcium concentrations (Chin et al., 1998).Myogenic functions of calcineurin in model genetic
systems
Drosophila calcineurin genes
Calcineurin subunit genes are conserved among animal
species, with the Drosophila genome containing three cna
and two cnb genes that are highly homologous to their
vertebrate relatives (Fig. 1). Historically, canA1 and canB
were isolated from a Drosophila embryonic cDNA library
by low stringency hybridization using human gene probes
(Guerini et al., 1992). The fly CnA1 protein is 73% identical
to human CnAa and CnAh, with catalytic motifs almost
completely conserved. Drosophila CnB is 88% identical to
human CnB1 and CnB2, with strong amino acid conserva-
tion within the four EF-hand calcium-binding motifs.
canB2, the second calcineurin regulatory gene of Drosoph-
ila, was discovered during the molecular analysis of the
cinnabar region of chromosome 2 (Warren et al., 1996). Its
encoded product is 98% identical to fly and 88% identical to
human CnB proteins. As for the two other cna genes, Pp2B-
14D was isolated from a Drosophila eye disc cDNA library
(Brown et al., 1994) and canA-14F was discovered through
the genome sequencing project (Adams et al., 2000). Pro-
teins encoded by either of these genes are 73–78% identical
to various human protein phosphatase 2B isoforms, with
near perfect conservation within their catalytic domains.
Therefore, all fly calcineurin proteins are predicted to
function comparably to their vertebrate counterparts.
Given these strong sequence identities, it made sense to
investigate the possible conservation of the calcineurin/
NFAT pathway in Drosophila and determine what functions
this signaling cassette might assume during fly development
and life processes. NFAT proteins contain a DNA-binding
domain of the rel class and comparative evolutionary
studies, based on the recent sequencing of numerous animal
genomes, has led to the categorization of Rel family proteins
(Graef et al., 2001b). Surprisingly, while the fly genome
encodes proteins like Dorsal, Dif, and Relish that are related
to the vertebrate transforming protein Rel and NFnB family,
calcium-responsive Rel proteins such as the NFAT group are
present only in vertebrates. That is, while certain Drosophila
genes may encode the conserved DNA-binding domain,
they do not possess sequences encoding a calcium/calci-
neurin-responsive domain that defines the calcium-depen-dent NFAT proteins. Thus, given the strong conservation of
calcineurin genes, and the absence of NFATc proteins from
the fly, a challenging question arises as to which proteins
might be effectors of calcineurin signaling in Drosophila.
One potential target for this pathway is noted below.
Screens for calcineurin interacting loci in Drosophila
Focused genetic screens can serve as powerful vehicles
to identify genes that function within defined developmental
processes and complex regulatory hierarchies. Considering
the involvement of calcineurin in several critical myogenic
events in vertebrates, and the potential to use genetic means
to identify new calcineurin interacting loci, Gajewski et al.
(2003) expressed an activated form of mouse CnA in
Drosophila muscles. For reasons yet unknown, such ex-
pression resulted in arrested animal development around
pupal day 1. Based on this occurrence, an F2 deficiency
screen was undertaken to search for chromosome intervals
that harbored genetic suppressors of the induced phenotype.
Animals hemizygous for seven distinct regions of Drosoph-
ila chromosomes 2 and 3 were able to suppress the
calcineurin-induced phenotype to adult viability. The stron-
gest suppressing deficiency corresponded to a deletion of
the 42B03–43E18 region of chromosome 2, with the canB2
gene mapping at 43E16. A P-element induced mutation of
canB2 by itself was able to prevent the lethality caused by
activated calcineurin expression. This suppression of phe-
notype demonstrated a normal dosage and function of the
calcineurin regulatory gene was needed for the adverse
effects of calcineurin on animal development and viability.
Another chromosome region identified in the screen
contained the D-mef2 gene at 46C and preliminary tests
using gene mutations suggested this muscle differentiation
factor contributed to the suppression activity of interval 3
(K. Gajewski and R.A. Schulz, unpublished data). Extensive
information has been generated on D-mef2, which is the sole
mef2 family member in the fly. D-MEF2 is expressed in all
differentiated muscles and their precursors during embryo-
genesis, and adepithelial cells that serve as precursors for
adult thoracic muscles (Bour et al., 1995; Lilly et al., 1995;
Ranganayakulu et al., 1995). Genetic studies have shown D-
mef2 is required for the proper differentiation of body wall,
heart, and visceral muscles during embryogenesis and
correct formation of dorsal longitudinal indirect flight
muscles (DLM) in the adult (Bour et al., 1995; Cripps and
Olson, 1998; Lilly et al., 1995; Ranganayakulu et al., 1995).
Given the known activation of a vertebrate MEF2 protein by
calcineurin in skeletal muscles of exercised mice (Wu et al.,
2001), further biochemical and genetic studies may prove
fruitful in identifying D-MEF2 as a direct transcriptional
effector of calcineurin signaling in Drosophila. Likewise,
the analysis of other suppressor genes within the remaining
five intervals should provide additional insights into those
proteins required for calcineurin function during muscle
formation.
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search for calcineurin interacting genes by screening for
dominant modifiers of a rough eye phenotype induced by
activated calcineurin expression. Four enhancing and five
suppressing complementation groups were identified in
these studies, with a major conclusion being that calci-
neurin functions with specific proteins to antagonize epi-
dermal growth factor receptor/Ras signaling in the eye
imaginal disc. canB2 was shown to be one of the sup-
pressor groups, demonstrating the shared importance of
this calcineurin regulatory gene in the eye and muscle
developmental assays. The remaining suppressor groups
identified in the eye screen map to different locations than
the suppressing intervals uncovered in the muscle screen,
indicating calcineurin activity requires several other to be
defined cell-specific factors in addition to canB2.
canB2 function is required for indirect flight muscle
formation in Drosophila
An analysis of strong canB2 mutations showed the gene
is essential for normal Drosophila development, with
mutants dying at a late larval/early pupal stage (Sullivan
and Rubin, 2002). However, genetic combinations involv-
ing weaker alleles result in adult escapers that are flightless
with wings positioned at abnormal angles (Gajewski et al.,
2003). This phenotype was suggestive of irregularities
among certain indirect flight muscle (IFM) groups in the
thorax. The events required for DLM formation in wild-type
animals are outlined in Fig. 5. DLM develop from three
pairs of larval oblique muscles that fail to histolyze during
metamorphosis within the pupal period (Fernandes and
Keshishian, 1996; Fernandes et al., 1991). These persistent
muscles split into six pairs that serve as a framework for
DLM formation, with muscle growth occurring due to the
ordered fusion of Twist-expressing adult myoblasts onto the
templates. When formed, the six central DLM pairs and
seven flanking pairs of dorsal ventral indirect flight muscles
(DVM) fill the adult thorax.
The analysis of IFM structure in canB2 mutant pupae
and adults revealed two reproducible phenotypes (Gajew-
ski et al., 2003). In animals that were able to eclose as
adults, abnormalities were observed in the DLM pattern
with most muscle pairs absent from anterior thoracic
sections and disorganized muscle masses present in poste-
rior sections. It was concluded that this phenotype was not
a result of the lack of larval muscle templates or initial
muscle formation, but due to the displacement of most
DLM to the posterior of the thorax. Presumably, sufficient
IFM integrity exists in these animals so as to facilitate
movement out of the pupal case. A more severe phenotype
was observed when IFM formation was followed in living
pupae using a sensitive MHC-GFP transgene muscle
marker (Chen and Olson, 2002). In animals that progressed
only to the pharate adult stage, a complete retraction of all
IFM to a posterior thoracic position was observed (Fig. 5).It is likely that such animals are unable to eclose due to
thoracic compression and/or insufficient IFM contraction,
resulting in lethality.
IFM retraction in canB2 animals is reminiscent of the
hypercontracted IFM phenotype found in certain myosin
heavy chain (Kronert et al., 1995) and troponin I (Kronert
et al., 1999) gene mutants. It is possible that calcineurin
activity is required for the modification of a myogenic
transcription factor, whose function is needed for the
activation (or repression) of specific IFM contractile pro-
tein genes. Genetic and molecular analyses should help to
identify the transcriptional regulator that serves as the
target of calcineurin phosphatase activity and the muscle
structural genes controlled by such a factor. Consistent
with the muscle phenotypes observed in mutant pupae and
adults, canB2 and the cna gene Pp2B-14D are expressed in
forming IFM, as well as in the central nervous system
(Gajewski et al., 2003). In contrast, calcineurin subunit
genes are not expressed in developing embryonic muscles,
indicating a clear specificity in calcineurin’s myogenic
function during Drosophila development.
Calcineurin expression and function in the nematode C.
elegans
While calcineurin subunits are encoded by multiple
genes in vertebrates and Drosophila, the C. elegans
genome contains a single gene for each of the highly
conserved proteins (Fig. 1). Worm CnA is encoded by the
cna-1/tax-6 gene and possesses a 77% overall amino acid
identity to a human isoform (Kuhara et al., 2002). tax-6
was initially discovered as a gene required as a negative
regulator of multiple signaling pathways in sensory neu-
rons. Expression studies showed this catalytic subunit is
present in diverse tissues and cell types including sensory
neurons, interneurons, body wall muscle, vulval muscle,
and spermatheca (Bandyopadhyay et al., 2002; Kuhara et
al., 2002). CnB is encoded by the cnb-1 locus and exhibits
80% identity with human and Drosophila proteins (Ban-
dyopadhyay et al., 2002). Enhancer-GFP expression and
protein immunostaining approaches confirmed the co-ex-
pression of CnB with CnA in hypodermal tissue, neurons,
muscle, and the male germline.
Consistent with the diverse expression of the tax-6 and
cnb-1 genes, phenotypic analyses identified cuticle defects,
small body size, decreased brood size, locomotion abnor-
malities, and egg-laying defects in the calcineurin gene
mutants. The latter two phenotypes are consistent with the
requirement of phosphatase activity in body wall and vulval
muscles. Excitingly, double mutants of cnb-1 and unc-
43(gf), which encodes a gain-of-function mutation of the
CaMKII protein kinase, show a synergistic severity of
animal movement and egg-laying defects (Bandyopadhyay
et al., 2002). Such results suggest that calcineurin and
CaMKII have opposing functions in these physiological
processes and highlight the potential of C. elegans as a
Fig. 5. Requirement of the canB2 gene for IFM formation in Drosophila. During normal development, three pairs of body wall muscles within the second
thoracic segment (T2) of third instar larvae fail to histolyze and persist into the pupal stage as templates for DLM growth. At specific times after puparium
formation (APF), the muscles split into six scaffold pairs and myoblasts fuse with these templates, generating six sets of DLM that eventually occupy most of
the adult thorax. While the initial steps of IFM formation appear normal in canB2 mutant animals, such muscles become abnormally organized and displaced to
a posterior thoracic position, likely due to hypercontractility of the muscle sets. Adapted in part from Fernandes and Keshishian (1996) and Gajewski et al.
(2003).
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calcineurin signaling.
It is noteworthy that nfatc homologues are absent from
the nematode genome (Graef et al., 2001b). Thus, as in
Drosophila, the effectors of calcineurin signaling remain
to be identified. Screens for genetic modifiers of worm
muscle phenotypes are likely to generate needed infor-
mation as to the targets of calcineurin activity. It is
plausible that as in vertebrates, MEF2 proteins may serve
as tissue-specific end points of calcineurin signaling in
both worms and flies. Unraveling the composition of
such calcineurin regulatory pathways should provide
fundamental insights into the role of the phosphatase in
basic cellular and physiological processes associated with
muscle formation and function. The absence of nfatc
genes from invertebrates may also speak to an evolution-
ary aspect of calcineurin signaling. That is, with the
increased complexity of vertebrate tissue and organ
development, calcium-dependent NFAT proteins may have
been recruited into this signal transduction network toprovide additional levels of biological regulation in cal-
cineurin-mediated events.Conclusions and perspectives
It is clear that through innovative genetic and physiolog-
ical approaches, much has been learned in recent years
about the importance of calcineurin signaling and NFAT
activation in the regulation of cardiovascular and skeletal
muscle development in vertebrate animals. With the emer-
gence of technological advancements for studying individ-
ual genes or gene networks within select tissues and cell
types, even greater knowledge of the intricacies of calci-
neurin signaling should be forthcoming. These predicted
advances in our understanding of regulatory interactions
will be especially important for those developmental pro-
cesses that when altered or aberrant, result in human health
risks or pathologies. The demonstration of the functional
requirement of invertebrate calcineurin genes in fundamen-
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portant progress and the use of highly sensitive genetic
methods in these model organisms should allow for the
identification and analysis of calcineurin interacting loci
unattainable by most other experimental approaches. Col-
lectively, the future looks quite promising to use combined
developmental and genetic approaches to more fully com-
prehend calcineurin signaling, its targets, and its regulators
in heart, vasculature, and muscle development and disease.Acknowledgments
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